Skip to contentA
Axim Biotechnologies, Inc.
A
AXIMAxim Biotechnologies, Inc. Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$12.61K$12.61Kderived+66.8% vs Q4 2022 Net Income-$1.90M-$1.90MderivedN/M vs Q4 2022 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Axim Biotechnologies, Inc. · CIK 1514946 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$753,941N/M Operating Cash Flowderived$19,556N/M Free Cash Flowderived$19,556N/M Margins · derivedOperating margin-5978.4%+9125.4 pt vs Q4 2022
Net margin-15083.9%−3193.3 pt vs Q4 2022
ended Dec 31, 2023 · filed Apr 16, 2024 · 107 d after period end